"CD40 Ligand" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A membrane glycoprotein and differentiation antigen expressed on the surface of T-cells that binds to CD40 ANTIGENS on B-LYMPHOCYTES and induces their proliferation. Mutation of the gene for CD40 ligand is a cause of HYPER-IGM IMMUNODEFICIENCY SYNDROME, TYPE 1.
| Descriptor ID |
D023201
|
| MeSH Number(s) |
D12.644.276.374.750.124 D12.776.395.550.185 D12.776.467.374.750.124 D12.776.543.550.198 D23.529.374.750.124
|
| Concept/Terms |
CD40 Ligand- CD40 Ligand
- gp39 Antigen, T-Cell
- T-Cell gp39 Antigen
- gp39 Antigen, T Cell
- CD40L
- Tumor Necrosis Factor Ligand Superfamily Member 5
- Antigen, CD154
- CD154 Antigen
- T-B Cell Activating Molecule
- TNF Superfamily, Member 5
- CD154 Antigens
- Antigens, CD154
|
Below are MeSH descriptors whose meaning is more general than "CD40 Ligand".
Below are MeSH descriptors whose meaning is more specific than "CD40 Ligand".
This graph shows the total number of publications written about "CD40 Ligand" by people in this website by year, and whether "CD40 Ligand" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 2 | 2 |
| 1997 | 0 | 2 | 2 |
| 1998 | 0 | 3 | 3 |
| 1999 | 0 | 2 | 2 |
| 2000 | 1 | 4 | 5 |
| 2001 | 6 | 3 | 9 |
| 2002 | 4 | 1 | 5 |
| 2003 | 4 | 2 | 6 |
| 2004 | 1 | 2 | 3 |
| 2005 | 5 | 2 | 7 |
| 2006 | 3 | 7 | 10 |
| 2007 | 0 | 3 | 3 |
| 2008 | 1 | 1 | 2 |
| 2009 | 4 | 0 | 4 |
| 2010 | 3 | 2 | 5 |
| 2011 | 2 | 2 | 4 |
| 2012 | 1 | 0 | 1 |
| 2013 | 2 | 1 | 3 |
| 2014 | 0 | 2 | 2 |
| 2015 | 1 | 1 | 2 |
| 2017 | 1 | 0 | 1 |
| 2019 | 1 | 0 | 1 |
| 2022 | 0 | 1 | 1 |
| 2023 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "CD40 Ligand" by people in Profiles.
-
Decoding the contextual duality of CD40 functions. Hum Immunol. 2023 Nov; 84(11):590-599.
-
Reactive metal boride nanoparticles trap lipopolysaccharide and peptidoglycan for bacteria-infected wound healing. Nat Commun. 2022 11 29; 13(1):7353.
-
Phoenix from the flames: Rediscovering the role of the CD40-CD40L pathway in systemic lupus erythematosus and lupus nephritis. Autoimmun Rev. 2020 Nov; 19(11):102668.
-
CD40 Ligand-Modified Chimeric Antigen Receptor T Cells Enhance Antitumor Function by Eliciting an Endogenous Antitumor Response. Cancer Cell. 2019 03 18; 35(3):473-488.e6.
-
Intratumoral CD40 activation and checkpoint blockade induces T cell-mediated eradication of melanoma in the brain. Nat Commun. 2017 11 13; 8(1):1447.
-
Quantitative activation suppression assay to evaluate human bone marrow-derived mesenchymal stromal cell potency. Cytotherapy. 2015 Dec; 17(12):1675-86.
-
A multi-trimeric fusion of CD40L and gp100 tumor antigen activates dendritic cells and enhances survival in a B16-F10 melanoma DNA vaccine model. Vaccine. 2015 Sep 11; 33(38):4798-806.
-
Human Infant Memory B Cell and CD4+ T Cell Responses to HibMenCY-TT Glyco-Conjugate Vaccine. PLoS One. 2015; 10(7):e0133126.
-
Enhancing antitumor efficacy of chimeric antigen receptor T cells through constitutive CD40L expression. Mol Ther. 2015 Apr; 23(4):769-78.
-
MicroRNA-155 influences B-cell receptor signaling and associates with aggressive disease in chronic lymphocytic leukemia. Blood. 2014 Jul 24; 124(4):546-54.